FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next >>
 
TXT Alkem Labs Hit With 10-item Form-483
04/09/2024
 
 
TXT Philips Respironics Consent Decree Approved
04/09/2024
 
 
TXT ViiV Wins Adolescent HIV Use for Dovato
04/08/2024
 
 
TXT Spirair Nasal Septal Deviation Device Cleared
04/08/2024
 
 
TXT Carvykti Approved for Expanded Myeloma Use
04/08/2024
 
 
TXT FDA 2nd Complete Response on Parkinson’s Drug
04/08/2024
 
 
TXT De Novo for Antibacterial Coated Implants
04/08/2024
 
 
TXT Shuffert Debarred for 5 Years
04/05/2024
 
 
TXT Abecma Expanded Approval for Multiple Myeloma
04/05/2024
 
 
TXT Honeywell Recalls Eyewash Cartridge
04/05/2024
 
 
TXT Accelerated Approval for Enhertu in Solid Tumors
04/05/2024
 
 
TXT Jubilant Generics Cited Over GMPs
04/05/2024
 
 
TXT AbbVie Urges FDA to Ban Unlicensed Thyroid Products
04/05/2024
 
 
TXT Withdraw AvertD Approval: Scientists
04/04/2024
 
 
TXT 45 CDRH Safety Communications in 2022: Report
04/04/2024
 
 
TXT Medos Guide Sheath Recall is Class 1: FDA
04/04/2024
 
 
TXT Liquidia Expects FDA Yutrepia Final OK Soon
04/04/2024
 
 
TXT Novartis Seeking Expanded Pluvicto Label
04/04/2024
 
 
TXT FDA Cross-Center AI Paper Analyzed
04/04/2024
 
 
TXT Califf in Hot Seat at 4/11 Oversight Hearing
04/04/2024
 
 
TXT Amylyx Pulls ALS Drug From the Market
04/04/2024
 
 
TXT OPQ Supported 55 Novel Drug Approvals in 2023
04/03/2024
 
 
TXT Ignore Former FDAer’s Comments: Sidley
04/03/2024
 
 
TXT New Indication for Vanda’s Fanapt
04/03/2024
 
 
TXT Bipartisan Bill on Drug-Gene Interactions
04/03/2024
 
 
TXT Contract Pharma Cited on Environmental Issue
04/03/2024
 
 
TXT HHS Defines FDA Roles in Drug Shortages
04/03/2024
 
 
TXT Abbott's TriClip OK'd for Tricuspid Regurgitation
04/03/2024
 
 
TXT FDA Qualifies Lethal Arrhythmia Database
04/03/2024
 
 
TXT FDA OKs Zevtera Antibiotic with 3 Indications
04/03/2024
 
 
TXT Prenosis AI Sepsis Predictor Authorized for Use
04/03/2024
 
 
TXT More Changes Urged in RRA Revised Guidance Comments
04/02/2024
 
 
TXT CGMP Violations at Mexico’s Betone SA de CV
04/02/2024
 
 
TXT Multiple Agena Bioscience Violations
04/02/2024
 
 
TXT QS Issues in Beckman Coulter Inspection
04/02/2024
 
 
TXT 20 Safety Potential Signals in 4th Quarter 2023
04/02/2024
 
 
TXT Bill to Speed Addiction Drug Treatments
04/02/2024
 
 
TXT Bioavailability/Bioequivalence Data Integrity Guide
04/02/2024
 
 
TXT Mixed Data on Colon Cancer Vaccine
04/02/2024
 
 
TXT Characterize Obesity as a Chronic Disease: Lilly
04/02/2024
 
 
TXT FDA Increasing Scrutiny of CooperSurgical IUD: Report
04/02/2024
 
 
TXT FDA Developing New Drug Safety Tools: Dal Pan
04/02/2024
 
 
TXT Baxter Novum IQ Large Volume Pump Cleared
04/01/2024
 
 
TXT AstraZeneca’s Voydeya OK’d for Hemolysis
04/01/2024
 
 
TXT Eisai sBLA for Monthly Alzheimer’s Maintenance
04/01/2024
 
 
TXT FDA Guide on Safety Report e-Submissions
04/01/2024
 
 
TXT FDA Clears Abbott’s Concussion Blood Test
04/01/2024
 
 
TXT PhRMA Seeks Specificity for Cell Product Potency Guide
04/01/2024
 
 
TXT Guide on Dental Bone Grafting Devices
03/29/2024
 
 
TXT Thoratec Recalls HeartMate Touch Communication
03/29/2024
 
 
TXT eSTAR Now Available for Device 513(g) Requests
03/29/2024
 
 
TXT ProJenX Partial Hold Lifted in ALS Study
03/29/2024
 
 
TXT Poll Backs FDA Status Quo in Approving Products
03/29/2024
 
 
TXT Guidance on IND Safety Report eSubmissions
03/29/2024
 
 
TXT Review Extended on Govorestat NDA
03/29/2024
 
 
TXT Dental Bone Graft Animal Study Guide
03/28/2024
 
 
TXT FDA Approves Akebia Vafseo for Some Anemias
03/28/2024
 
 
TXT Aldeyra Plans for Reproxalap NDA Resubmission
03/28/2024
 
 
TXT 3-year-old Fusion IV FDA-483 Released
03/28/2024
 
 
TXT ASCA Pilot Met, Exceeded Expectations: CDRH
03/28/2024
 
 
TXT Amneal Recalls 4 Lots of Vancomycin
03/28/2024
 
 
TXT FDA OKs Expanded Use for Hepatitis B Drug
03/28/2024
 
 
TXT Medexus’ Hemophilia B Factor Gets Expanded Use
03/28/2024
 
 
TXT 2 REMS Assessment MAPPs
03/27/2024
 
 
TXT FDA ‘Fails to Follow Science’ in Electroshock Case: Attorneys
03/27/2024
 
 
TXT BIO Suggestions for CGT Potency Guidance
03/27/2024
 
 
TXT Catalent Indiana FDA-483
03/27/2024
 
 
TXT Merck BLA for Winrevair Approved
03/27/2024
 
 
TXT Proposed Ban on Certain e-Stimulation Devices
03/27/2024
 
 
TXT Weiner Moves to Foreign Inspections Office
03/27/2024
 
 
TXT Boston Scientific Recalls PolarSheath Steerable
03/27/2024
 
 
TXT FDA Approves Medtronic Evolut FX+
03/27/2024
 
 
TXT Revised BA/BE Sample Handling Guidance
03/26/2024
 
 
TXT Bioresearch Monitoring Issues at New York Site
03/26/2024
 
 
TXT Mesoblast Refiling BLA for Remestemcel-L
03/26/2024
 
 
TXT CGMP Violations at Deqing Jiarou
03/26/2024
 
 
TXT Multiple Violations in ReNovo Inspection
03/26/2024
 
 
TXT Rep. Questions Musk Device Trial OK Before Inspection
03/26/2024
 
 
TXT Antibody Drug Conjugate Guidance Explained
03/26/2024
 
 
TXT High Court Skeptical on Mifepristone Restrictions
03/26/2024
 
 
TXT Clinical Data Interchange Standards Update
03/26/2024
 
 
TXT Quantitative Medicine Center of Excellence Created
03/25/2024
 
 
TXT J&J’s Opsynvi OK’d for Pulmonary Hypertension
03/25/2024
 
 
TXT Regeneron Complete Response on Lymphoma BLA
03/25/2024
 
 
TXT FDA Again Seeks Ban on Shock Devices
03/25/2024
 
 
TXT GAO Report Hits FDA on Investigator Retention
03/25/2024
 
 
TXT Arrow QuickFlash Radial Artery Catheter Recall
03/22/2024
 
 
TXT Italfarmaco Wins Approval for Duchenne Drug
03/22/2024
 
 
TXT FTC Challenges Teva Orange Book Listings
03/22/2024
 
 
TXT FDA Settles Ivermectin Messaging Lawsuit
03/22/2024
 
 
TXT Clarity in RWE Guidance is Welcome: Attorneys
03/22/2024
 
 
TXT Organon Wants Generic Nexplanon Restrictions
03/21/2024
 
 
TXT 4 Observations in Medi-Fare Inspection
03/21/2024
 
 
TXT FDA Grants, Denies Draize Test Petition
03/21/2024
 
 
TXT AdvaMed on Metallic Coatings Characterization
03/21/2024
 
 
TXT Safety Labeling Changes for Fluorouracil Injection
03/21/2024
 
 
TXT Vyaire Recalls AirLife Resuscitators
03/21/2024
 
 
TXT Hearing Challenges FDA Rule on LDTs
03/21/2024
 
 
TXT Phase 3 Keytruda Miss in Lung Cancer
03/21/2024
 
 
TXT Elixir Gets ‘Breakthrough’ for DynamX BTK
03/21/2024
 
 
<< Prev  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving